Edwards Lifesciences stock

EW · NYSE · USD

Compare Edwards Lifesciences
$105.43Change from previous close: −1.57%Absolute change: −$1.68

Close · November 17, 2026

Price history

+26.17% over the period

1 year: from $84.74 (November 17, 2025) to $106.92 (November 17, 2026), +26.17%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$106.92
October 30, 2026$92.01
September 30, 2026$86.32
August 31, 2026$90.75
July 31, 2026$86.07
June 30, 2026$90.46
May 29, 2026$86.47
April 30, 2026$83.50
March 31, 2026$80.08
February 27, 2026$86.47
January 30, 2026$81.36
December 31, 2025$85.25
November 28, 2025$86.67
November 17, 2025$84.74

At a glance

  • The company

    Develops and distributes heart valve replacement and repair products for minimally invasive and surgical cardiovascular treatments

  • Latest results

    Quarter to September 30, 2026 · EPS $0.80 (estimate $0.74)

TickerLandia's take on Edwards Lifesciences

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$74.66
52-wk high$108.00

−2.38% from the 52-week high

Analysts · 30 analysts

Average target$113.39+7.55% vs. price

Buy 25 · Hold 4 · Sell 1 · Buy

TickerLandia Fingerprint: Edwards Lifesciences

Compared with similar companies: very high financial strength, very strong momentum, and very high price.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Edwards Lifesciences is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Edwards Lifesciences's P/E today is 58.4, above the median of its last 8 fiscal years (45.9; between 10.6 and 70.2 from 2018 to 2025). Edwards Lifesciences's P/E (trailing 12 months): 61.6, +96% against the median of a group of 11 similar companies (31.4).

P/E compared with its history

Compared with 11 similar companies

Edwards Lifesciences's metrics compared with similar companies
MetricEdwards LifesciencesPosition in the groupBand
P/E (trailing 12 months)61.6High
Forward P/E31.6High
Operating margin28.8%High
ROE9.3%Low
Debt/equity0.06Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Edwards Lifesciences. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.72B

Latest quarter · Q3 2026

Net income

$307.5M

Latest quarter · Q3 2026

Quarterly net margin

17.9%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$61.59B
P/E
61.6
EPS
$1.74
Volume
4.05M
Daily trading
€447.24M
Dividend yield
0.00%

How Edwards Lifesciences is changing

All results
  • Revenue grew 6.7% a year on average over the last 5 years

  • Operating margin fell from 33.6% to 20.8%

  • Less cash than profit: free cash flow equal to 34% of net income

Returns

Edwards Lifesciences returns

$1,000 invested in Edwards Lifesciences 5 years ago, on November 17, 2021, would be worth $903 today: −9.66% in total, −2.01% per year. This is the price return only: dividends are excluded.

PeriodEdwards LifesciencesS&P 500$1,000 becomes
1 month+22.59%−3.17%$1,226
6 months+29.55%+0.11%$1,296
Year to date+25.42%+8.34%$1,254
1 year+26.17%+11.15%$1,262
3 years+59.82%+64.30%$1,598
5 years−9.66%+58.18%$903
10 years+253.57%+239.10%$3,536

Over the last 6 months it has done better than 67% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Edwards Lifesciences: technical analysis

Edwards Lifesciences is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 19.3% below its all-time closing high ($130.68, December 30, 2021).

Trend
Upward
RSI (14 sessions)
73
Above 70: a strong rise in a short time
vs 200-session average
+21.78%

Active signals

  • RSI above 70: the stock has risen a lot in a short time.

    since November 4, 2026

Support and resistance

Price areas where Edwards Lifesciences has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$105.43
  3. Support$93.43−11.38%2 touches, last on September 1, 2026
  4. Support$89.59−15.02%2 touches, last on September 16, 2026
  5. Support$87.97−16.56%7 touches, last on November 2, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.54
Volatility (60 sessions, annualised)
25.1%
Largest fall in the last year
−13.19%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Edwards Lifesciences: seasonality

Average monthly price change over 27 years

+1.8%Jan+1.5%Feb+2.1%Mar+3.4%Apr+2.8%May+3.5%Jun+0.2%Jul+1.9%Aug−1.0%Sep−2.5%Oct+3.3%Nov+4.2%Dec

Over the last 27 years, the strongest month for Edwards Lifesciences has been December: +4.23% on average, positive in 16 years out of 26. The weakest has been October: −2.49% on average, positive in 14 years out of 27. November, the current month, has been positive in 18 years out of 26 (+3.32% on average).

Show chart data
MonthAverageMedianPositive years
January+1.81%+1.66%15 of 26
February+1.48%+1.68%15 of 26
March+2.12%+1.77%19 of 26
April+3.36%+4.27%18 of 27
May+2.82%+2.89%19 of 27
June+3.52%+4.61%18 of 27
July+0.21%+1.03%15 of 27
August+1.93%+1.15%18 of 27
September−1.03%−2.45%10 of 27
October−2.49%+0.39%14 of 27
November+3.32%+3.85%18 of 26
December+4.23%+3.84%16 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Edwards Lifesciences and its competitors

Edwards Lifesciences sells products and technologies for the treatment of advanced cardiovascular diseases to patients and clinicians in the United States, Europe, Japan and other international markets. Its core offering is transcatheter heart valve therapy, including the SAPIEN valve family for replacing aortic valves without open-heart surgery and the PASCAL and EVOQUE systems for treating mitral and tricuspid valve disease. The company also supplies surgical structural heart products such as the INSPIRIS and INSPIRIS RESILIA aortic valves, the KONECT RESILIA valve conduit and the MITRIS RESILIA valve.

Headquarters
Irvine, United States
Employees
16,000
Founded
1958
Chief executive
Bernard Zovighian
Edwards Lifesciences and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Edwards LifesciencesEW$61.59B28.8%61.6+29.55%
Boston ScientificBSX$63.33B19.6%18.4−18.32%
GE HealthCare TechnologiesGEHC$37B13.8%17.3+34.69%
StrykerSYK$118.29B24.0%33.1+3.51%
DexComDXCM$30.44B24.0%32.1+33.12%
MedtronicMDT$132.22B20.1%25.4+34.37%

Same industry or related industries, similar size. Compare Edwards Lifesciences with its competitors · Full profile